Broad compatibility increases lab consistency.
Continued Process Verification (CPV), Process Analytical Technology (PAT) and Quality by Design (QbD), are driving pharma to improve product and process quality and efficiency.
This article explains how using an Octet-based Fc receptor panel may help developers achieve a faster assessment of monoclonal antibody functionality, well before the final molecule is selected.
Today’s chemical development labs are busy places that create fascinating new chemicals, new formulations and new products that boost the bottom line. But are these labs as efficient as they could be?
Identifying the optimal formulation and dose form which shows an increase more than 20 times in the oral bioavailability of Salmon Calcitonin.
This BIOVIA customer uniquely combines the reach and resources of a major pharmaceutical company with the entrepreneurial spirit and agility associated with the world of biotech. The company focuses on a range of illnesses including cancer, cardiovascular disease, diabetes, hepatitis B, HIV/ AIDS, rheumatoid arthritis and psychiatric disorders. Their R&D organization prioritizes pipeline velocity and sales growth while continuing to manage costs.
Taking overall equipment effectiveness (OEE) into consideration provides clear guidance on maximizing productivity. But, which factors affect OEE and how do you get started on the path to optimization?
As the nature of the target molecule becomes increasingly challenging, the need is to move away from the current linear and siloed drug development approach.
Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry recently announced the launch of the ambr® 250 high throughput (ht) perfusion, a new automated parallel bioreactor system.